BLA
IOVA icon

Balter Liquid Alternatives’s Iovance Biotherapeutics IOVA Stock Holding History

Balter Liquid Alternatives’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,254
Closed -$138K – 230
2018
Q3 		$138K Hold
12,254
– – 0.11% 159
2018
Q2 		$163K Buy
12,254
+1,588
+15% +$23.2K 0.13% 163
2018
Q1 		$180K Sell
10,666
-13,508
-56% -$205K 0.17% 142
2017
Q4 		$193K Buy
24,174
+1,565
+7% +$12.6K 0.19% 128
2017
Q3 		$175K Buy
22,609
+10,936
+94% +$69.2K 0.2% 123
2017
Q2 		$86K Buy
+11,673
New +$74.2K 0.1% 124

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balter Liquid Alternatives's IOVA Position: Q4 2018 in Review

Balter Liquid Alternatives sold out of Iovance Biotherapeutics (IOVA) in Q4 2018, closing a stake of 12,254 shares — an estimated $138K sold.

Balter Liquid Alternatives first reported a position in IOVA in Q2 2017 and held it in 6 quarters. The position peaked at $193K in Q4 2017. 139 funds tracked by Wall St. Rank hold IOVA as of Q4 2018.

  • Balter Liquid Alternatives reported no remaining Iovance Biotherapeutics position as of Q4 2018 after selling out during the quarter.
  • Balter Liquid Alternatives sold 12,254 Iovance Biotherapeutics shares in Q4 2018, an estimated $138K.
  • Balter Liquid Alternatives first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 6 quarters.
  • Balter Liquid Alternatives's Iovance Biotherapeutics position peaked at $193K in Q4 2017.
  • 139 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2018.

Based on Balter Liquid Alternatives's 13F filing for Q4 2018, filed 8 Feb 2019.